You cannot diagnose what you cannot see: The importance of optimized imaging protocols for accurate disease staging and assessment
Authors:
- 10 July 2023
- journal article
- editorial
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (10) , e30552
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Clinical trials: A plea to cooperative groups, consortia, pharmaceutical companies, and lead investigators for reasonable imaging protocolsPediatric Blood & Cancer, 2023
- Imaging of pediatric brain tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee/ASPNR White PaperPediatric Blood & Cancer, 2022
- Efficacy of Carboplatin and Isotretinoin in Children With High-risk MedulloblastomaJAMA Oncology, 2021
- Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk MedulloblastomaJournal of Clinical Oncology, 2021
- MBCL-36. HOW TO INCREASE SURVIVAL IN 7 TO 10% OF PATIENTS WITH AVERAGE-RISK MEDULLOBLASTOMA WITHOUT NEW THERAPIES: EARLY PROSPECTIVE NEURORADIOLOGY SCREENING EXPERIENCE FROM THE CHILDREN’S ONCOLOGY GROUPNeuro-Oncology, 2020
- Improving the outcome for children with cancer: Development of targeted new agentsCA: A Cancer Journal for Clinicians, 2015
- Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk MedulloblastomaJournal of Clinical Oncology, 2006